PainReform Ltd.
PRFX
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conductingā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.00
Price-0.99%
-$0.01
1Y
Price
Market Cap
$80.532k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-12717.6%
EBITDA Margin-14835.3%
Net Profit Margin-11617.6%
Free Cash Flow Margin-12717.6%
EBITDA Margin-14835.3%
Net Profit Margin-11617.6%
Free Cash Flow MarginRevenue
$17k
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$4.838m
+66.8%
1y CAGR+1.5%
3y CAGR-4.2%
5y CAGREPS
-$7.47
+96.2%
1y CAGR+63.6%
3y CAGR+44.8%
5y CAGRBook Value
$9.290m
$11.998m
Assets$2.708m
Liabilities$21k
DebtDebt to Assets
0.2%
-
Debt to EBITDAFree Cash Flow
-$3.957m
+68.7%
1y CAGR-7.9%
3y CAGR-5.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company